everolimus + cetuximab + irinotecan

This is a **combination therapy** consisting of three distinct agents: **everolimus** (an mTOR inhibitor), **cetuximab** (an epidermal growth factor receptor, EGFR, monoclonal antibody), and **irinotecan** (a topoisomerase I inhibitor). The combination has been investigated primarily for use in **metastatic colorectal cancer (mCRC)** that has progressed after first-line chemotherapy. The rationale for this combination is to target multiple pathways involved in tumor growth and resistance: everolimus inhibits the mTOR pathway, cetuximab blocks EGFR signaling, and irinotecan inhibits DNA replication via topoisomerase I inhibition. Emerging data indicate some feasibility and clinical activity for this regimen as second-line therapy, but the combination is not standard or widely approved, having been mostly evaluated in early-phase clinical studies. Dose-limiting toxicities and protocol amendments due to adverse effects have been reported in trials, and the clinical development of this triple combination is limited due to changes in standard of care and toxicity concerns[1][2][4].